Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Manulife Financial Corporation (MFC) vs Summit Therapeutics Inc (SMMT) Price & Performance

Manulife Financial CorporationTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Manulife Financial Corporation vs Summit Therapeutics Inc — how do they compare? Manulife Financial Corporation trades at $44.13 (market cap $72.68B), while Summit Therapeutics Inc trades at $15.26 (market cap $12.06B). The key difference: Manulife Financial Corporation is far larger — about 6× Summit Therapeutics Inc's market cap, and Manulife Financial Corporation pays a 3.1% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

MFCSMMT
Market Cap
$72.68B$12.06B
Sector
FinancialsHealth
52-Week High
$44.77$26.98
52-Week Low
$30.06$12.55
Enterprise Value
$67.84B$11.39B
Dividend Yield
3.1%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Manulife Financial Corporation

Manulife Financial (MFC) trades at $44.09, down slightly by 0.14% today, with a neutral technical signal and mixed earnings performance. The company reported strong Q2 2026 results with 12% core earnings growth and 21% APE sales growth in Asia, though Q1 results missed expectations. Revenue has grown from $15.3B in 2022 to $53.0B in 2025, with net income margin at 11.7% and ROE of 13.88%. Recent partnerships with Microsoft and Alibaba Cloud highlight strategic AI investments.

MFC presents a balanced outlook with solid fundamentals and growth in Asian markets, supported by a 57% analyst buy rating and $51.50 price target. However, premium valuation (P/E 16.57, P/B 2.18) and mixed technical indicators suggest cautious optimism. Key risks include execution in wealth management, regulatory scrutiny in Hong Kong, and macroeconomic sensitivity. The stock offers steady dividends with recent $0.49 payouts.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.

Returns comparison

Trailing returns across standard periods

About Manulife Financial Corporation

Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.

Read more on MFC

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT